Pfizer buying spree continues with $5.4 billion hematology deal

Pfizer also announced in April a smaller acquisition to buy the privately held ReViral Ltd., which is developing a treatment for respiratory syncytial virus

Pfizer
The latest deal follows Pfizer's $11.6 billion acquisition of Biohaven, which the companies announced in May
Press Trust of India New York
2 min read Last Updated : Aug 08 2022 | 9:41 PM IST

Pfizer will spend about USD 5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets for treating sickle cell disease. Oxbryta sales were about $195 million last year.

The latest deal follows Pfizer's $11.6 billion acquisition of Biohaven, which the companies announced in May, and a $6.7 billion acquisition of Arena Pharmaceuticals announced last December.

Pfizer also announced in April a smaller acquisition to buy the privately held ReViral Ltd., which is developing a treatment for respiratory syncytial virus.

Pfizer Inc.'s top-selling COVID-19 vaccine and treatment have left the New York City drugmaker flush with cash to spend on an acquisition feel. The vaccine and treatment brought in more than $16 billion combined just in the recently completed second quarter.

Aamir Malik, the company's chief business innovation officer, told analysts recently that Pfizer was leaving very few stones unturned in looking for expansion opportunities. Malik said Pifzer was looking for deals that will speed up growth in the back half of the decade and can add substantial value either scientifically or commercially.

I think we're very excited about the opportunities that are ahead of us and the flexibility that our balance sheet gives us to pursue those, he said during a call to discuss second-quarter results.

Pfizer will pay $68.50 per share in cash for each share of Global Blood Therapeutics.

Both companies' boards have approved the deal, which still needs regulatory approval and approval from GBT shareholders.

Shares of Global Blood Therapeutics Inc., based just outside San Francisco, rose 4% before the opening bell. Shares of Pfizer were essentially flat.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Pfizerpharmaceutical firmsPharma Companies

First Published: Aug 08 2022 | 9:41 PM IST

Next Story